Objectives: The aim was to assess the effectiveness and safety of catheter-directed thrombolysis in children with deep venous thrombosis and to evaluate its long-term effect. Method and results: EMBASE, Medline and Cochrane databases were searched to identify studies in which paediatric acute deep venous thrombosis patients received thrombolysis. Following title and abstract screening, seven cohort studies with a total of 183 patients were identified. Technical success was 82% and superior in regional rather than systemic thrombolysis (p < 0.00001). One cohort study identified significant difference in thrombus resolution at one year between thrombolytic and anticoagulant groups (p ¼ 0.01). The complication rate was low, with incidence rates of major bleeding, pulmonary embolism and others at 2.8%, 1.8% and 8.4%, respectively. The overall post-thrombotic syndrome rate was 12.7%. The incidence of re-thrombosis ranged from 12.3% to 27%. Conclusion: Thrombolysis for paediatric deep venous thrombosis is an effective and relatively safe therapeutic option, lowering the incidence of post-thrombotic syndrome and deep venous thrombosis recurrence.
Background
Deep vein thrombosis (DVT) in children is relatively rare but can cause serious acute and chronic complications with significant morbidity, such as clot extension, recurrence, pulmonary embolism, chronic venous insufficiency and post-thrombotic syndrome (PTS). 1 The currently recommended standard therapy for DVT in adults and children is anticoagulation with unfractionated heparin or low-molecular-weight heparin (LMWH), often followed by warfarin. This regimen coincides with the American College of Chest Physicians(ACCP) guidelines. 2, 3 Systemic or catheterdirected medical thrombolysis, using a tissue plasminogen activator (tPA) such as alteplase, can increase the speed and extent of clot resolution, thereby decreasing the risk of post-thrombotic syndrome. 1 In adults, small series have suggested that thrombolysis is more effective than unfractionated heparin therapy in decreasing the risk of PTS without increasing the rate of bleeding complications. [4] [5] [6] [7] The American Heart Association (AHA) guidelines suggest consideration for such therapy in paediatric patients in whom the balance of benefit to risk may be most favourable. 8 However, the current ACCP guidelines discourage the routine use of thrombolytic therapy for paediatric DVT and many clinicians limit the use of tPA in children because of concerns about serious bleeding complications. Regarding the PTS in children, the clinical findings of pain, swelling and brown induration are similar to adult patients. 8 Clearly, the primary focus should be on prevention of initial thrombosis. So, the paediatricians should be aware of the potential of PTS in all children who are at risk of DVT. 9 The aim of this review is to collate evidence on the effectiveness of thrombolysis in deep venous disorders among paediatric population and their effect on the development of PTS, the safety of the regimen, thrombosis recurrence, as well as the impact of different antithrombotic agents.
Methods

Study selection
Research question as well as inclusion and exclusion criteria of the studies were specified in advance (see Table 1 ). The population of this review consists of paediatric patients who underwent deep venous thrombolysis by catheter-directed thrombolysis (CDT) and/or percutaneous pharmaco-mechanical thrombolysis (PPMT). Studies in which not all participants were thrombolysed were also included, as were any studies with more than participants. Interrogation of MEDLINE, EMBASE and COCHRANE databases using the OVIDsp (Ovid Technologies, Inc.) platform from 1946 up to mid-October of 2016 was undertaken. The search strategy can be found in online Appendix 1. Medical subject headings (MeSH) were used for keyword and text word searching and free text for word searching only. No publication date restrictions were imposed. However, the search was restricted to articles in English and Arabic. Further selection was made on title and abstract screening. The final selection of articles was made after reviewing the full text as per the preferred reporting standards for systematic reviews and meta-analysis (PRISMA) (see Figure 1 ). 10 Two researchers (MAHT and AB) independently selected studies for inclusion in the review. Titles and abstracts were initially screened to exclude review articles, commentaries, letters, case reports and obviously irrelevant studies. Full texts of the remaining articles were retrieved and reviewed.
Quality assessment
Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE Working Group) were used for the included full text articles in the review. The results of the GRADE assessment are displayed in online Appendix 2.
11 Studies were screened by two authors (MAHT and AB), and any discrepancies were adjudicated by a third author (AHD).
Data analysis
Technical success rates in all the included studies were recorded together with post-thrombotic manifestations, thrombosis recurrence, complications, thrombophilia assessment, anti-coagulation used and the duration of therapy. The results were tabulated using ExcelTM (Version 1706, Microsoft, Redmond, USA). Statistical analysis was performed using SPSS 20.0 software (IBM, USA) and RevMan 5. 
Results
Inclusion and quality assessment
The search strategy resulted in a total of 76 studies, and after applying exclusion criteria and screening title, abstract and full text, as per PRISMA guidelines, 10 seven studies were eventually included in the qualitative synthesis, but none qualified for quantitative synthesis ( Figure 1 ). The studies consisted of seven cohort studies (two prospective 12, 13 and five retrospective studies 1, [14] [15] [16] [17] ). The findings of the search are summarized in Table 2 .
Level of the evidence and GRADE
The quality of evidence to support the use of thrombolysis in the management of upper limb (UL) and lower limb (LL) venous thromboembolism is currently weak. Using the GRADE approach for the eight defined outcomes, the quality of evidence was rated as Low as it largely pooled from cohorts and case series. The findings have been summarized in Table 3 .
Risk of bias
The included studies were evaluated individually for the presence of any systematic errors in their results (bias) that can lead to underestimation or overestimation of the true intervention effect. 11 The included studies were assessed for several key biases by MAHT: selection bias, performance bias, detection bias, attrition bias and selective reporting bias. Attrition bias was deemed an elevated risk if the follow-up rate was less than 80%, in the absence of systematic examination of those participants who were lost to follow-up. Bias was also evaluated at outcome level using the GRADE assessment of the evidence. The risk assessment of bias in the included studies is summarized in Figure 2 . Also, Newcastle-Ottawa Quality Scale (NOS) 18 was used to assess the risk of bias and quality of methodology of the included seven cohort studies. NOS was developed to assess the quality of non-randomized studies with its design, content and ease of use directed to the task of incorporating the quality assessments in the interpretation of meta-analytic results. A 'star system' has been developed in which a study is judged on three broad perspectives: the selection of the study groups; the comparability of the groups; and the ascertainment of either the exposure or outcome of interest for case-control or cohort studies respectively. 18 
Outcomes
Population demographic. One hundred and eighty-three children with 190 limbs (40 UL and 150 LL) had been received thrombolysis in all of included studies with mean age of 12.6 years. All patients had received thrombolytic therapy for either upper or lower extremity thrombosis in the form of systemic or regional thrombolytic therapy using tissue plasminogen activator (tPA). About 7.3% of children had received adjunctive therapy in the form of venoplasty and stents placement. In 71% of studies, patients had received postinterventional anticoagulation therapy in the form of low molecular weight heparin (LMWH) or warfarin for a period of at least 3-6 months. Patient characteristics are illustrated in Table 2 .
Site of the thrombus. In all included studies, 98.8% of children had been reported with venous thromboembolic events including upper and lower extremities with a ratio of 1:3.9. However, two patients recorded thrombosis within the right atrium. In all reported patients, the dominant sites of involved venous segments had been recorded and summarized in Figure 3 .
Technical success of thrombolysis. Technical success and effectiveness of thrombolysis were assessed in all (7/7) studies. 1, [12] [13] [14] [15] [16] [17] The overall technical success of thrombolysis in all included studies among paediatric population was 82%, with better effectiveness among children subgroups when using regional rather than systemic thrombolysis (91.7% vs. 63%), but with low level of evidence see Table 5 . One cohort study identified significant statistical difference of >90% thrombus resolution at one-year follow-up between thrombolytic against anticoagulant groups (88.9%; 8/9 vs. 41.7%; 5/13; p ¼ 0.01).
14 The overall technical successes are summarized in Table 2 .
Recurrent DVT. The DVT recurrences were assessed in 2/7 (28.5%) studies with low reported recurrence rate with 12.3% at median 1.5 years' follow-up 17 and 27%
at median 14 months follow-up. 12 The overall DVT recurrence rate among children in the reported studies was 15% of patients. The DVT recurrence data are summarized in Table 2 .
Post-thrombotic syndrome
Complications (procedure safety). PTS was assessed in 71% (5/7) of studies. [12] [13] [14] 16, 17 Recognized tools of the assessment of chronic venous manifestations were only employed in four studies (Villalta and Modified Villalta: 2; clinical class of the Clinical-EtiologyAnatomic-Pathophysiologic (CEAP): 2). The overall PTS rate was 12.7% of children in studies that reported PTS as an outcome measure. All PTS data are summarized in Table 2 .
Thrombophilia assessment. Thrombophilia factors evaluation was reported in all (7/7) included studies.
1,12-17 Thrombophilia factors survey was employed in 97.1% of children in all studies, with at least 85% of patients were positive with either congenital or acquired hypercoagulable status. All thrombophilia factors data are summarized in Table 2 .
The complication rates following CDT were reported in all of included studies. 1, [12] [13] [14] [15] [16] [17] The overall incidence of complications were rates of major bleeding of 2.8%, PE 1.8% and others (including minor bleeding from access site) 8.4%. Major complication rates were 4.6% in all studies. The most serious complication of thrombolytic therapy reported in all studies remains major bleeding events, commonly recognized as (1) intracranial haemorrhage (ICH), (2) retroperitoneal haemorrhage, (3) bleeding requiring surgical intervention and (4) drop in haemoglobin of 2 g/dL 24 hours following therapy. 8 All available complication for all included studies data are summarized in Table 4 .
Adjunctive procedure. Adjunctive therapy (venoplasty AE stenting) has been reported in 4/7 (57.1%) studies with 7.3% of the population receiving stents within their venous segments. All these patients had received WALL stents due to either residual stenosis or MayThurner syndrome. We noticed that all stented patients were aged 11 years or more. In a study reported by Gaballah et al., stents were placed in 6.3% of patients, with an average age of 16.8 years, for the treatment of residual venous stenosis or residual transmural thrombus resistant to thrombolysis. 17 In addition, endovascular stents were deployed in all cases of May-Thurner anomaly recorded by the study conducted by Goldenberg et al. 12 Among the five subjects with May-Thurner anomaly in whom percutaneous mechanical thrombolysis (PMT)/percutaneous pharmaco- mechanical thrombolysis (PPMT) was performed within six weeks of symptom on-set, with a median follow-up duration of 10 months, locally recurrent DVT developed in two subjects, both with severe underlying thrombophilia. 12 Quality of life assessment and the mean length of hospital stay. The quality of life questionnaire and mean length of hospital admission were employed in one study for each respectively. 12, 15 Abnormalities on both the chronic pain findings as part of the WongBaker component and those on the physical findings based on CEAP component of the Manco-Johnson instrument were 13% (95% CI: 0.1%-49%). 12 
Subgroups
We identified 183 paediatric patients (190 limbs) with venous thrombosis who received thrombolysis. Fiftyfour patients received regional lysis (28.4%) compared to 134 patients who received systemic lysis (70.5%). Using propensity-matched comparison, the technical success rate was significantly lower in the systemic lysis group compared to the regional lysis group (63% compared to 91.7%; 2 23.2 and p < 0.00001) (see Table 5 ).
Discussion
The optimal therapy for many forms of venous thromboembolism (VTE) in infants and children remains undefined. 19 Thrombolytic therapies in children do not have well-established indications 20 and are unsupported, such as with the American College of Chest Physicians guidelines discouraging the routine use of thrombolytic therapy for paediatric deep venous thrombosis, 2 unless in life or limb-threatening thrombosis (Grade 2C). The American Heart Association (AHA) guidelines, however, suggest consideration for such therapy in young patients, in whom the balance of benefit to risk may be most favourable. 21 However, evidence supporting such recommendations is not strong, and actual clinical practice in this arena is poorly defined and appears to vary significantly. 13, 14, 20, 22 Comparative studies regarding thrombolysis versus anticoagulation are still lacking in the paediatric population. After the assessment of both the risk of bias and quality of methodology of the seven cohort studies using Newcastle-Ottawa Scale, four studies 1, 12, 14, 17 have been detected with high quality and score of more than 7 (see Table 6 ).
Our search noted an overall technical success rate of 82% with a low incidence of major bleeding rate of 2.8%. Although this overall thrombolysis effectiveness is good enough to ensure the success of the procedure, these figures are affected by the low level of evidence according to the GRADE assessment, as most of studies are case series (see Table 3 ). Meta-analysis of venous thrombolysis in paediatric population could not be conducted in this review due to lack of robustly constructed randomised controlled trials.
Initially, the plan was to compare systemic to regional lysis, but this was not possible as only data available were on technical aspects in which tPA as a thrombolytic agent had been used for thrombolysis in all included studies.
The overall PTS rate was 12.7% among children, who had received thrombolysis as definitive regimen of therapy and reported in studies that considered PTS as an outcome measure. The CEAP classification has been used alone in children and alongside the Wong-Baker pain scale, becoming the Manco-Johnson instrument, 23 which has been validated for use in patients aged 1-21 years, with a score of 1 or more diagnostic of PTS. In the study reported by Goldenberg et al., 12 the cumulative incidence of any PTS (physical findings on the basic CEAP component or chronic pain findings on the Wong-Baker component of the Manco-Johnson instrument) at 1-2 years was 80% (95% CI: 48%-95%), whereas that of physically and functionally significant PTS (i.e., abnormalities on both components of the instrument) was 13% (95% CI: 0.1%-49%).
Paediatric findings with the use of a standardized PTS scoring system (adapted from the Villalta scale) were first published in 2003 in a retrospective analysis by the Childhood Thrombophilia Program at the Hospital for Sick Children. 24 This study reported a prevalence of PTS of 63%. Prospective evidence with a paediatric PTS outcome measure, the Manco-Johnson instrument (for which validation data were subsequently published 14 ), has indicated a cumulative incidence of PTS (as defined by physical or functional findings) of 33% at 1-2 years among unselected children. 25 Children under 18 with significant PTS have a worse quality of life compared to children with mild or no PTS, particularly in the psychosocial, social and physical domains of the Paediatric Quality of Life Inventory. 26 The CaVent Study, a randomized controlled clinical trial, has shown that early thrombus removal with thrombolysis is safe and effective in adults with acute proximal DVT. However, this therapy is only available at selected centres with appropriate expertise for children 19 and, so far, has not shown a significant improvement in the quality of life. The ATTRACT trial, completed recently, also casts further doubt on the effectiveness of interventional procedures for lower limb DVT in adults. 27 The study failed to show an improvement in lower limb PTS rates following above knee DVTs, although demonstrated a probable benefit for ilio-femoral DVT. This further highlights the need for a greater understanding of the development of PTS.
A recent survey of members of the American Society of Paediatric Hematology/Oncology members approach to the treatment of paediatric VTE indicated no prevailing consensus regarding thrombolytic therapy indication, dosing, duration, mode of delivery, or desirability of concurrent anticoagulation administration. 19 Although hereditary thrombophilia factors play a major role development of deep venous thrombosis among paediatric population, 75% of population reported in the study by Kno¨fler et al., have been detected without any hereditary hypercoagulable factors. 15 However, in a study recorded by Goldenberg et al., late local recurrences were restricted in all cases to patients with severe hypercoagulability (such as asparaginase-induced multiple thrombophilias, severe protein S deficiency, antiphospholipid antibody syndrome), with or without underlying stenotic venous lesions. Furthermore, a low risk of recurrent VTE after iliac vein stent placement for May-Thurner anomaly has been reported in children without severe underlying thrombophilia. 12 Experience in the use of thrombolytic therapy for paediatric acute DVT is rapidly evolving, and a recent, small controlled single-institutional study has suggested a potential benefit in the efficacy and safety of specific thrombolytic approaches. 12 The incidence rate of surgical site bleeding has been reported in 8.4% of children in all studies. In study reported by Wang et al., 13 50% of paediatric population who meet their study inclusion criteria had minor bleeding complications. However, studies recorded by Goldenberg et al., 12, 14 Leary et al. 1 and Kno¨fler et al. 15 reported no cases of bleeding from the venepuncture sites.
More recently, bleeding association with thrombolytic therapy appears to be decreasing in both the paediatric and adult populations. This is likely due to improved risk stratification and greater experience with thrombolytic dosing regimens and local approaches, including CDT therapy and percutaneous mechanical thrombolysis PMT/percutaneous pharmacomechanical thrombolysis PPMT. 8 In the context of safety consideration, children were treated with tPA 13 and based on local clinical decisions. Initially, dosing was based on published recommendations of 0.1 to 0.5 mg/kg per hour. 28 However, standards of safety and efficacy in the treatment of paediatric DVT with thrombolytic therapy remain to be determined. 8 Although tPA has shown efficacy in thrombolysis of arterial as well as venous thromboses in paediatric patients from preterm infants through adolescents, 29 to our knowledge, no enough data are available to suggest if whether complication rate following thrombolysis within venous system is lower than lysis of arterial thrombosis in paediatric population. However, a metaanalysis of studies 29 summarizing the experience of tPA thrombolysis of arterial and venous thrombi in neonates compared to infants and children reported that bleeding toxicity was comparable in all four groups of paediatric patients with major haemorrhage in approximately 10%. Minor bleeding occurred in almost half of treated patients. Intracranial haemorrhage, while uncommon, occurred primarily in high-risk newborn infants. 29 Although the experience of using stent placement after thrombolytic therapy for paediatric acute DVT needs to be thoroughly searched, our search noted 7.3% of paediatric patients were managed with venoplasty with stent placement. All these patients had received WALL stents within their venous segments due to either residual stenosis or May-Thurner syndrome. In addition, we noticed that all stented patients were aged 11 years or more. This, of course, will raise another important question about stenting in this age group of patients and to consider whether the accelerated growth of puberty symptoms 30, 31 may play a role in changing haemodynamics related to DVT which needs further research evaluation.
There are, therefore, still several areas of uncertainty regarding the most appropriate management of DVT in this patient population. Further studies comparing regional thrombolysis against conservative measures with longer term follow-up as well as adequate outcome measures in children to include validated CVD measures and QOL scores are awaited. 32 In addition, the growing need for more participation of basic science in clinical trials should be considered to support their findings.
Limitations
This study has some limitations. A meta-analysis could not be performed because of a lack of RCTs. According to the GRADE assessment, the quality of most of the included studies was low as all of the studies were cohort and case series. The thrombophilic factors assessment was incompletely studied, and the underlying hypercoagulable causes were unclear in some studies and not thoroughly reviewed to measure it as a separate outcome in all the included studies. Detailed information regarding DVT recurrences in all the included studies are lacking and either they had occurred while patients were under anticoagulant or not. In addition, the quality of life questionnaires had not been used in all of the included studies.
Conclusion
Deep venous thrombolysis for paediatric acute DVT of both upper and lower extremities appears to be an effective therapeutic option and relatively safe procedure and reduces the incidence of post-thrombotic syndrome and recurrent DVTs.
Incomplete understanding of risks and benefits of therapy limit widespread practice of thrombolysis in both adult and paediatric DVT. Published guidelines vary with respect to their recommendations for thrombolytic therapy in paediatric patients with DVT. Further comparative studies with higher level of evidence would allow for a better assessment of the safety and efficacy of thrombolytic approaches in the paediatric population and would, hopefully, enable a reduction in the mortality and morbidity, including the effect on the quality of life of patients.
What this paper adds
This review demonstrates that the quality of evidence behind the effectiveness of deep venous thrombolysis among paediatric population for the treatment of acute deep venous thrombotic events is weak. This review intended to serve a guide for the future research.
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